InsidersTradesSigma
Track the BIOSYNEX stock price and the full directors' dealings record of the company, a listed issuer based in France. Shares are quoted on the FR market, under the oversight of AMF. Operating in the Healthcare & Pharma sector, BIOSYNEX has logged 103 public disclosures. Market capitalisation: €17m. The latest transaction was disclosed on 28 February 2025 (Acquisition). Among the most active insiders: LARRY ABENSUR. The full history is accessible without an account.
103
Insider Decl.
n/a
Thresholds
€2m
41 ops.
Buy Volume
€8m
51 ops.
Sell Volume
51Σ signal
Fundamental score
Ranked 27,719 of 29,064 companies
15.3
score / 100
Value4
Quality26
FCF yld-51%
Earn yld·
EV/EBITDA·
ROE-96%
Gross mgn55%
Net mgn-61%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 February 2025
Declarations103 total
25,000 shares@ €1.280.6% of flowActionEuronext Growth ParisISIN FR00110059332025DD1022653
Canonical exit: 26 May 2025 (T+90)
11,169 shares@ €1.31420.3% of flowActionEuronext Growth ParisISIN FR00110059332025DD1022654
Canonical exit: 28 May 2025 (T+90)
42,987 shares@ €1.13080.9% of flowActionEuronext Growth ParisISIN FR00110059332025DD1020600
Canonical exit: 20 May 2025 (T+90)
42,987 shares@ €1.13080.9% of flowActionEuronext Growth ParisISIN FR00110059332025DD1021002
Canonical exit: 13 May 2025 (T+90)
1,599 shares@ €1.000.0% of flowActionEuronext Growth ParisISIN FR00110059332025DD1020913
30,586 shares@ €1.0015.7% of flowActionEuronext Growth ParisISIN FR00110059332025DD1020918
13,832 shares@ €1.0095.8% of flowActionEuronext Growth ParisISIN FR00110059332025DD1020943
43,187 shares@ €1.19291.0% of flowActionEuronext Growth ParisISIN FR00110059332025DD1020898
Canonical exit: 15 May 2025 (T+90)
49,017 shares@ €1.201.1% of flowActionEuronext Growth ParisISIN FR00110059332025DD1020899
Canonical exit: 18 May 2025 (T+90)
55,590 shares@ €1.001.1% of flowActionEuronext Growth ParisISIN FR00110059332025DD1020908
4,542,837 shares@ €1.0099.5% of flowActionEuronext Growth ParisISIN FR00110059332025DD1020911
30,741 shares@ €1.30350.8% of flowActionEuronext Growth ParisISIN FR00110059332025DD1020743
Canonical exit: 14 May 2025 (T+90)
10,975 shares@ €0.0453.4% of flowDPSEuronext Growth ParisISIN FR001400WOK32025DD1018760
282,952 shares@ €0.01100.0% of flowDPSHors plateforme de négociationISIN FR001400WOK32025DD1018144
107,036 shares@ €0.010.1% of flowDPSHors plateforme de négociationISIN FR001400WOK32025DD1018145
627,651 shares@ €0.010.1% of flowDPSHors plateforme de négociationISIN FR001400WOK32025DD1018146
168,184 shares@ €0.010.0% of flowDPSHors plateforme de négociationISIN FR001400WOK32025DD1018147
994,796 shares@ €0.01100.0% of flowDPSHors plateforme de négociationISIN FR001400WOK32025DD1018149
2,180,619 shares@ €0.010.5% of flowDPSHors plateforme de négociationISIN FR001400WOK32025DD1018140
Canonical exit: 28 Apr 2025 (T+90)
1,000 shares@ €0.11720.8% of flowDPSEuronext Growth ParisISIN FR00110059332025DD1017643
2,500 shares@ €12.20196.6% of flowActionEuronext Growth ParisISIN FR00110059332023DD884526
Canonical exit: 11 May 2023 (T+90)
2,500 shares@ €12.27016.6% of flowActionEuronext Growth ParisISIN FR00110059332023DD884527
Canonical exit: 14 May 2023 (T+90)
1,000 shares@ €17.47093.8% of flowActionEuronext Growth ParisISIN FR00110059332022DD822689
Canonical exit: 23 May 2022 (T+90)
1,800 shares@ €17.310.6% of flowActionEuronext Growth ParisISIN FR00110059332022DD822670
Canonical exit: 22 May 2022 (T+90)
5,200 shares@ €17.811.8% of flowActionEuronext Growth ParisISIN FR00110059332022DD822686
Canonical exit: 22 May 2022 (T+90)
25 of 103 declarations
关于 BIOSYNEX
BIOSYNEX 是一家法国医疗保健集团，专注于快速诊断测试 (RDT) 以及更广泛的旨在改善患者护理的医疗保健解决方案的设计、制造和分销。公司成立于 2005 年，总部位于阿尔萨斯伊尔基希-格拉芬斯塔登，已逐渐发展成为体外诊断领域公认的参与者，业务遍及 90 多个国家。该集团拥有 330 多名员工，服务于广泛的客户群，包括医学检验实验室、医院、药店和其他医疗保健分销渠道。BIOSYNEX 定期公布其发展战略和财务日历，使其成为医疗保健中小盘股投资者密切关注的股票。 BIOSYNEX 的业务历来围绕快速测试展开，即旨在在护理点或实验室环境中提供简单、可靠和快速结果的医疗设备。其产品范围涵盖多个医疗领域，并面向各种疾病的检测、筛查和监测。该集团还强调其工业和监管专业知识，并获得 ISO 9001 和 ISO 13485 认证支持，这些认证是医疗诊断行业的关键基准。多年来，BIOSYNEX 通过有机增长和收购进行扩张，以加强其技术组合、地理足迹和进入新市场的能力。 该公司近期历史的一个显著部分是其在 2024 年和 2025 年的财务和组织重组工作，同时继续发展其诊断业务和药房部门。BIOSYNEX 还完成了在相邻诊断和医疗保健业务领域的多次收购和整合项目。这些举措旨在巩固其在有吸引力的增长市场中的地位，同时提高其国际影响力并丰富产品种类。 从地理上看，BIOSYNEX 在法国拥有强大的基础，同时在国际上创造了可观的收入份额。其业务模式结合了产品设计、生产和分销，使其能够控制选定领域的完整价值链。在对创新、诊断速度和监管合规性至关重要的严苛医疗保健环境中，BIOSYNEX 将自己定位为快速检测和相关解决方案的专家，具有专注于公共卫生和更快获得诊断的法国实验室的形象。
